spacer
home > ict > spring 2019 > e pluribus unum: out of many, one
PUBLICATIONS
International Clinical Trials

E Pluribus Unum: Out of Many, One

Drug development is a brutally competitive industry, with the total capitalised cost of bringing a successful new drug to market now exceeding US $2.5 billion, and, despite significant increases in R&D expenditure, returns are diminishing with experimental drugs gaining regulatory approval falling to one in 10. Adding to this dilemma are the costs associated with conducting clinical trials, which have risen at a rate 7.4% higher than inflation.

Life sciences organisations are in a race against time to reduce the ‘innovation gap’ in drug development and costs and are exploring numerous ways to curtail development timelines and increase the odds of successfully bringing new treatments to market, cumulating in significant investment in eClinical tools. According to research conducted by the Tufts Center for the Study of Drug Development, investments are bearing fruit, with 80% of organisations who have invested in eClinical technology reporting time savings and 30% shorter cycle times in comparison to those with inadequate technologies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Craig Morgan is responsible for directing the global marketing strategy and team for the Oracle Health Sciences suite of study startup applications, working with sponsors, CROs, medical device manufacturers, and sites to reduce cycle times and improve collaboration and oversight in clinical trials. Craig is a technology and life sciences management professional with over 15 years’ experience in the application of informatics and bioinformatics to drug discovery and eClinical technology associated with starting clinical trials. He holds degrees in analytical chemistry, information systems, and business administration and is a certified project manager with the Project Management Institute.
spacer
Craig Morgan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Regulatory bottlenecks mean EU clinicians and patients could lose access to medical devices under new rules

European clinicians and their patients could lose access to vital medical devices, including in-vitro diagnostics, due to a lack of agencies able to certify products in time to comply with strict new regulations.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

Clinical Innovation Partnerships

11-12 September 2019, Hotel Palace, Berlin

Clinical Innovation Partnerships is the only event for senior clinical operations and procurement professionals driving innovation in their clinical trials. It is where the pharma, CRO and vendor clinical trials ecosystem meet to drive innovation in digitalisation, tech and partnering to improve patient experience and reduce trial cost and time.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement